Tumor Imaging Metrics

The mission of the Tumor Imaging Metrics Core (TIMC) is to provide standardized, consistent, longitudinal, multimodality radiological measurements to evaluate therapeutic response for patients enrolled in DF/HCC clinical trials.

Overview

The Tumor Imaging Metrics Core (TIMC):

  • Makes reliable, quantitative, longitudinal measurements (such as RECIST, Lugano, RANO, standardized uptake value [SUV] etc.) of lesions from serial MRI, CT, PET, and PET/CT scan images
  • Presents results of analyses on a password protected secure web-based report
  • Provides an independent service, with verifiable measurement of treatment response for patients enrolled in cancer center trials
  • Serves as a centralized, computerized resource to facilitate efficient internal or external auditing

Reliable tracking of changes in lesion size or metabolism is essential for clinical trials that use radiological measurements as surrogate endpoints. The Tumor Metrics Core provides a service for managing these images, making measurements in a routine, reliable, and centralized way, and making results available to investigators efficiently.

Group Members

Core Co-Director: Gordon Harris, PhD (MGH)
Core Co-Director: Annick Van den Abbeele, MD (DFCI)

Core Manager:
Gina Basinsky
Tel: 617-643-7812
gbasinsky@partners.org

Research Fellows:

Vikram Kurra, MD
Tel: 617-643-0437
vkurra@partners.org

Supriya Somarouthu, MD
Tel: 617-643-7143
bsomarouthu@partners.org

Samira Farough, MD
Tel: 617-643-7998
sfarough@partners.org

Nency Joshipura, MD
Tel: 617-643-0258
njoshipura@partners.org

Atul Padole, MD
Tel: 617-643-0106
apadole@partners.org

Facilities & Equipment

Location of Core: 25 New Chardon Street Suite 501, Boston, MA 02114

Major Equipment:

  • HERMES workstation
  • Merge Healthcare eFilm workstation
  • Vitrea workstation

Services

  • Consultation services for image-based protocol and image analysis design
  • Image capture and management of multimodality scans from all DF/HCC institutions
  • Tumor measurements from scans of patients on clinical trials according to trial protocol
  • Web-based reporting of results with annotated images and results summary
  • Database management of radiological data for clinical trials
  • Quality Control:
    • For site review, the TIMC paradigm utilizes one central reader per radiologic exam (single read). The central reader will be randomly assigned and cannot be selected by trial staff based on site location.
    • A mediation process has been established in the instance that the central review is felt to be discordant with clinical assessment. Trial staff should file a request for mediation with the TIMC Help Desk (tumormetrics@partners.org) which will trigger a review by a blinded, independent reviewer at a site where the patient is not enrolled.
    • A randomly selected subset of imaging studies are reviewed by dedicated TIMC staff to ensure that documentation was made to justify discordance between central radiology and clinical reviews. Additionally, data are reviewed to ensure appropriate disease was selected at baseline and that follow-up assessments were rendered according to established criteria.
  • Radiology reviewer training:
    • Radiologists and Image Analysts are trained and certified as proficient in established response assessment criteria and clinical research principles.
  • Standardized lesion measurement:
    • Standardized, longitudinal image measurement of radiological scans for oncology clinical trials.

Fee Schedule

Included in the TIMC user fees are the following services; consultation with Trial PIs prior to trial initiation, image study capture from DF/HCC centers, image study archival for the length of the trial, tumor measurements as specified in the protocol, database management of measurement results and image snapshots, web-based results reporting and assistance with trial audits with respect to the image analysis components of the trial.

The TIMC offers consultative services to clinical trials investigators at no additional cost to DF/HCC investigators. The goal of the consultative service is to optimize clinical trials’ protocol design for imaging acquisition and analysis methods so that trials are established with appropriate and optimal imaging methods.

TIMC service fees (per scan). Updated 1-December 2017

Assessment Criteria   DF/HCC member   
  Industry sponsored
RECIST, RECIST1.1 ch/ab/pel (CT/MR)   $100   $300
WHO, MacDonald ch/ab/pel (CT/MR)   $100   $300
irRECIST ch/ab/pel (CT/MR)   $150   $450
IWG Cheson 1999 or IWG Cheson 2007 (CT or PET/CT)   $125   $375
Lugano 2014 (+ Deuville Score, (CT or PET/CT)   $125   $375
LYRIC 2016, (+Deuville Score), (CT or PET/CT)   $125   $375
irRC (CT/MR)   $150   $375
IWCLL, spleen and liver measurements   $125   $375
PCWG2 + RECIST1.0 or 1.1   $125   $375
PCWG3 + RECIST1.0 or 1.1   $150   $450
MDA Bone   $100   $300
RANO 2010 (Radiographic Assessment Only), (MR w/ contrast and T2 FLAIR)                      $150   $450
RANO1.1 2015 (Radiographic Assessment Only), (MR w/contrast)   $175   $425
iRANO (Radiographic Assessment Only), (brain MR w/contrast)   $175   $425
3D Volume, neuro, maximum of 2 lesions (brain MR w/ contrast)   $150   $450
3D Volume, neuro, over 2 lesions (brain MR w/contrast)   $200   $500
IPCG (Radiographic Assessment Only)   $100   $300
SUV Neuro, maximum of 5 lesions (PET)   $125   $375
SUV Whole Body, maximum of 5 lesions (PET)   $125   $375
IMWG (CT/bone scan)   $125   $375
IWRC (CT or PET/CT)   $125   $375
Choi, (CT w/contrast)   $150   $450
Dual Criteria (2 criteria per trial) Please consult with TIMC as process vary

 

Getting Started

Contact:

Core Manager
Gina Basinsky
Tel: 617-643-7812

TIMC Help Desk
Tel: 617-643-7813
tumormetrics@partners.org

Back to Top